REV-ERB agonist is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-10-09. Numbers and descriptions here follow the published literature rather than marketing material.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also referred to as Stenabolic in non-scientific contexts. |
| Chemical class | Synthetic small molecule | Not a steroid or peptide hormone. |
| Receptor target | REV-ERBα and REV-ERBβ | Nuclear receptor agonist in preclinical studies. |
| Development status | Investigational | No approved human therapeutic indication. |
| Regulatory attention | Prohibited in sport | Listed by anti-doping authorities. |
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
In order to avoid the stigma of a restaurant chain, Smashburger crafts local burgers for each city where it is located and markets them extensively. These burgers are designed after consulting with distributors for the kinds of ingredients that are most shipped to a particular city or geographic area. For instance, Smashburger's Colorado locations serve burgers with roasted green chiles, while locations in Miami serve burgers with grilled chorizo. In Minneapolis, the chain has a double-cheese, double-onion variety evoking Scandinavian and Germanic cuisine. Its Oklahoma variety features locally popular fried pickles, while Boston locations serve a burger with onions and a cranberry chutney supplied locally by Ocean Spray. The burgers tend to be original creations as opposed to duplicating local flavors; in the case of Minneapolis the chain deliberately avoided selling a burger that would resemble the locally renowned Jucy Lucy. There are exceptions, such as in Kalamazoo and Grand Rapids restaurants, where the local burger is topped with olives, a tradition that had once been locally popular. The restaurant attracted criticism from health experts for the unhealthiness of some of its menu offerings. A large BBQ Bacon and Cheddar Smashburger has 1,050 calories, while a Chocolate Oreo Shake has 950 calories. Initially, the restaurant made only larger burgers and marketed large servings as a value add, but as it grew it began to offer different sizes to appeal to a larger audience.
=== Other locations === Every Halloween since 1969, a pumpkin has been impaled onto the spire of North Miami Public Library by a group named Coxie's Army. This has become a celebrated tradition, and is often accompanied by the hanging of a poem at the library's entrance. At the University of Montana, a pumpkin has been placed on the spire of the Main Hall every October since 1995. These pranks resulted in arrests on charges of trespassing in 2004 and 2016.
===== MeSH D08.811.682.664 – oxidoreductases acting on ch-nh2 group donors ===== MeSH D08.811.682.664.249 – amine oxidase (copper-containing) MeSH D08.811.682.664.500 – amino acid oxidoreductases MeSH D08.811.682.664.500.062 – alanine dehydrogenase MeSH D08.811.682.664.500.125 – d-amino-acid oxidase MeSH D08.811.682.664.500.261 – d-aspartate oxidase MeSH D08.811.682.664.500.398 – glutamate dehydrogenase MeSH D08.811.682.664.500.410 – glutamate dehydrogenase (nadp+) MeSH D08.811.682.664.500.470 – glutamate synthase (NADPH) MeSH D08.811.682.664.500.484 – glutamate synthase (NADH) MeSH D08.811.682.664.500.498 – glycine decarboxylase complex MeSH D08.811.682.664.500.498.500 – glycine dehydrogenase (decarboxylating) MeSH D08.811.682.664.500.526 – glycine dehydrogenase MeSH D08.811.682.664.500.677 – l-amino acid oxidase MeSH D08.811.682.664.500.724 – leucine dehydrogenase MeSH D08.811.682.664.500.772 – nitric oxide synthase MeSH D08.811.682.664.500.772.249 – nitric oxide synthase type i MeSH D08.811.682.664.500.772.500 – nitric oxide synthase type ii MeSH D08.811.682.664.500.772.750 – nitric oxide synthase type iii MeSH D08.811.682.664.500.810 – proline oxidase MeSH D08.811.682.664.500.848 – protein-lysine 6-oxidase MeSH D08.811.682.664.500.924 – valine dehydrogenase (NADP+) MeSH D08.811.682.664.750 – monoamine oxidase MeSH D08.811.682.664.750.100 – benzylamine oxidase
== Function == The protein encoded by this gene is the predominant constituent of the crystalline core of the eosinophil granule. High levels of the proform of this protein are also present in placenta and pregnancy serum, where it exists as a complex with several other proteins including pregnancy-associated plasma protein A (PAPPA), angiotensinogen (AGT), and C3dg. This protein may be involved in antiparasitic defense mechanisms as a cytotoxin and helmintho-toxin, and in immune hypersensitivity reactions. It is directly implicated in epithelial cell damage, exfoliation, and bronchospasm in allergic diseases. PRG2 is a 117-residue protein that predominates in eosinophil granules. It is a potent enzyme against helminths and is toxic towards bacteria and mammalian cells in vitro. The eosinophil major basic protein also causes the release of histamine from mast cells and basophils, and activates neutrophils and alveolar macrophages.
The major point of contention is that heavy advertising for these procedures, in combination with a lack of public education, fosters body insecurities in women with larger labia in spite of the fact that there is normal and pronounced individual variation in the size of labia. The preference for smaller labia is a matter of a fashion fad and is without clinical or functional significance.
Sources: en.wikipedia.org
Molomo described the Selous Scouts in 2009 as "a terrorist unit within the Rhodesian security forces". Piers Brendon wrote in 2010 that "the Selous Scouts committed the worst atrocities" of any Rhodesian unit. Ian Martinez has written that the Selous Scout's killings of prisoners and use of chemical and biological weapons were war crimes.
Selenium compounds commonly exist in the oxidation states −2, +2, +4, and +6. It is a nonmetal (more rarely considered a metalloid) with properties that are intermediate between the elements above and below in the periodic table, sulfur and tellurium, and also has similarities to arsenic.
Over 2003–2013 for companies that approved 8–13 drugs, the cost per drug could rise to as high as $5.5 billion, due mainly to international geographic expansion for marketing and ongoing costs for Phase IV trials for continuous safety surveillance. Alternatives to conventional drug development have the objective for universities, governments, and the pharmaceutical industry to collaborate and optimize resources. An example of a collaborative drug development initiative is COVID Moonshot, an international open-science project started in March 2020 with the goal of developing an un-patented oral antiviral drug to treat SARS-CoV-2.
The second tier consists of several dozens of midsized companies, with sales in the range of $100–$250 million per year. Their portfolios comprise both custom manufacturing and API-for-generics. They include both independents and subsidiaries of major companies. A number of these companies are privately owned and have grown mainly by reinvesting the profits. Examples are Bachem, Switzerland; Dishman, India; F.I.S. and Poli Industria Chimica, Italy; Hikal, India, and Hovione, Portugal. Customers prefer to do business with mid-sized companies, because communications are easier — they typically deal directly with the decision maker — and they can better leverage their purchasing power. The third tier includes thousands of small independents, with sales below $100 million per year. Most of them are located in Asia. They often specialize in niche technologies. The minimum economical size of a fine chemical company depends on the availability of infrastructure. If a company is located in an industrial park, where analytical services, utilities, safety, health, and environmental (SHE) services, and warehousing are readily available, there is practically no lower limit. New fine chemical plants have appeared mostly in Far East countries over the past few years. Their annual turnover rate rarely exceeds $25 million. All big and medium-size fine chemical companies have cGMP-compliant plants that are suitable for the production of pharmaceutical fine chemicals.
The placula hypothesis, proposed by Otto Bütschli, holds that the last common ancestor of animals was an amorphous blob with no symmetry or axis. The center of this blob rose slightly above the silt, forming a hollow that aided feeding on the sea floor underneath. As the cavity grew deeper and deeper, the organisms resembled a thimble, with an inside and an outside. This body shape is found in sponges and cnidaria. This explanation leads to the formation of the bilaterian body plan; the urbilaterian would develop its symmetry when one end of the placula became adapted for forward movement, resulting in left-right symmetry. The planula hypothesis, proposed by Bütschli, suggests that metazoa are derived from planula; that is, the larva of certain cnidaria, or the adult form of the placozoans. Under this hypothesis, the larva became sexually mature through paedomorphosis, and could reproduce without passing through a sessile phase. The gastraea hypothesis was proposed by Ernst Haeckel in 1874, shortly after his work on the calcareous sponges. He proposed that this group of sponges is monophyletic with all eumetazoans, including the bilaterians. This suggests that the gastrulation and the gastrula stage are universal for eumetazoans. It has been perceived as problematic that gastrulation by invagination is by no means universal among eumetazoans. Only recently has an invagination been confirmed in a Calcarea sponge, albeit too early to form a remaining inner space (archenteron).
Sources: en.wikipedia.org
== External links == Ashton CH (2002). Benzodiazepines: how they work & how to withdraw (aka The Ashton Manual). Archived from the original on 17 July 2023. Retrieved 4 May 2024. Ashton CH (2007). "Benzodiazepine equivalence table". Fruchtengarten L (April 1998). Ruse M (ed.). "Benzodiazepines". Poisons Information Monograph (Group monograph) G008. International Programme on Chemical Safety INCHEM. Retrieved 9 June 2009. Longo LP, Johnson B (April 2000). "Addiction: Part I. Benzodiazepines—side effects, abuse risk and alternatives". American Family Physician. 61 (7): 2121–2128. PMID 10779253. Archived from the original on 12 May 2008. Retrieved 25 May 2008.
The MMR vaccine (abbreviated as MMR) is a combination vaccine against measles, mumps, and rubella (German measles). It contains the combined measles vaccine, mumps vaccine, and rubella vaccine into a single injection. After two doses, 97% of people are protected against measles, 88% against mumps, and at least 97% against rubella. The vaccine is also recommended for those who do not have evidence of immunity, those with well-controlled HIV/AIDS, and within 72 hours of exposure to measles among those who are incompletely immunized. It is given by injection. Measles is a highly contagious viral illness that can lead to serious complications, including pneumonia, acute encephalitis, and, in rare cases, long‑term neurological disease. Pregnant women are at increased risk of severe respiratory complications and adverse pregnancy outcomes such as pregnancy loss and premature birth. The MMR vaccine is widely used around the world. As of 2012, 575 million doses had been administered since the vaccine's introduction worldwide. Measles resulted in 2.6 million deaths per year before immunization became common. This has decreased to 122,000 deaths per year as of 2012, mostly in low-income countries. Through vaccination, as of 2018, rates of measles in North and South America are very low. Rates of disease have been seen to increase in populations that go unvaccinated. Between 2000 and 2018, vaccination decreased measles deaths by 73%. Side effects of immunization are generally mild and resolve without any specific treatment.
21st International Symposium on Chirality STEREOISOMERISM - OPTICAL ISOMERISM Symposium highlights-Session 5: New technologies for small molecule synthesis IUPAC nomenclature for amino acid configurations. Michigan State University's explanation of R/S nomenclature Chirality & Odour Perception at leffingwell.com Chirality & Bioactivity I.: Pharmacology Chirality and the Search for Extraterrestrial Life "The Handedness of the Universe" by Roger A Hegstrom and Dilip K Kondepudi, Scientific American, January 1990
To demonstrate South African commitment to Namibian independence, Botha permitted a moderate, multi-party coalition to create a South West African interim government in August 1983, known as the Multi-Party Conference and subsequently as the Transitional Government of National Unity. Provision was made for an executive and legislative assembly, and the new government was bestowed with all the powers formerly held by the territory's Administrator-General. The rise of an interim government was accompanied by a defence policy dubbed "Namibianisation", a reference to the Vietnamization programme the US had pursued during the Vietnam War. Increasingly the South African war effort rested on what limited white manpower could be raised in South West Africa itself, and local black units drawn from the San, Ovambo, Kavango, and Lozi ethnic groups. The main objectives of Namibianisation were to establish a self-sufficient military infrastructure in South West Africa, reduce casualty rates among South African personnel, and reinforce the perception of a domestic civil conflict rather than an independence struggle. The SADF had started recruiting black South West Africans in 1974 and established segregated military and paramilitary units for semi-autonomous tribal entities such as Ovamboland two years later. PLAN had previously benefited from the deployment of white South African conscripts, reservists, and policemen unfamiliar with the terrain or environment; indigenous recruits were perceived as a means of mitigating this disadvantage.
=== Air spread === An air spread will include the breathing air supply equipment, and often a deck decompression chamber. Where a chamber is present, facilities for hyperbaric oxygen treatment are usually required. If the planned decompression is to be long, a diving stage or bell and the associated handling equipment is likely to be included to allow better control of ascent rate and decompression depth. Equipment for in-water or surface decompression on oxygen (SurDO2) may be available. Equipment may be necessary to facilitate safe entry to and exit from the water, and may include extrication equipment in case the diver is injured. A basic offshore air diving spread will typically include a dive control unit with compressor and high pressure storage banks, a launch and recovery system with a wet bell, a deck decompression chamber and a hot water unit.
Sources: en.wikipedia.org
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.
No. It is a small molecule that binds nuclear receptors involved in circadian regulation. Its classification differs from anabolic steroids or peptide hormones.
Published human clinical trial data are lacking. Most safety and activity information comes from preclinical models, so effects in people remain uncertain.
Liquid chromatography-tandem mass spectrometry is a common approach. It can detect the parent compound and its metabolites in biological matrices.